ES2052872T3 - Procedimiento de inactivacion de virus. - Google Patents

Procedimiento de inactivacion de virus.

Info

Publication number
ES2052872T3
ES2052872T3 ES89122657T ES89122657T ES2052872T3 ES 2052872 T3 ES2052872 T3 ES 2052872T3 ES 89122657 T ES89122657 T ES 89122657T ES 89122657 T ES89122657 T ES 89122657T ES 2052872 T3 ES2052872 T3 ES 2052872T3
Authority
ES
Spain
Prior art keywords
virus inactivation
acid
inactivation procedure
protein products
products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89122657T
Other languages
English (en)
Spanish (es)
Inventor
Richard L Seng
John L Lundblad
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Application granted granted Critical
Publication of ES2052872T3 publication Critical patent/ES2052872T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/806—Drug, bio-affecting and body treating compositions involving IgM
    • Y10S424/807—Monoclonal
    • Y10S424/808—Human
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal
    • Y10S530/865—Human

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES89122657T 1988-12-20 1989-12-08 Procedimiento de inactivacion de virus. Expired - Lifetime ES2052872T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/287,368 US4939176A (en) 1988-12-20 1988-12-20 Viral inactivation process

Publications (1)

Publication Number Publication Date
ES2052872T3 true ES2052872T3 (es) 1994-07-16

Family

ID=23102591

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89122657T Expired - Lifetime ES2052872T3 (es) 1988-12-20 1989-12-08 Procedimiento de inactivacion de virus.

Country Status (9)

Country Link
US (1) US4939176A (https=)
EP (1) EP0374625B1 (https=)
JP (1) JP2601551B2 (https=)
AT (1) ATE82510T1 (https=)
AU (1) AU618157B2 (https=)
CA (1) CA1340211C (https=)
DE (1) DE68903558T2 (https=)
ES (1) ES2052872T3 (https=)
GR (1) GR3006561T3 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001367A1 (en) * 1989-07-20 1991-02-07 Bioeng, Inc. Supercritical fluid disruption of and extraction from microbial cells
US5202246A (en) * 1989-08-16 1993-04-13 Armour Pharmaceutical Company Treatment of immobilized matrices for preparation of pharmaceutical and biological products with anti-microbial agents to remove pyrogen-producing organisms and pyrogens
AU6428390A (en) * 1989-08-16 1991-04-03 Rorer International (Overseas) Inc. Treatment of immobilized matrices with antimicrobial agents to remove pyrogen-producing organisms and pyrogens
JPH0671434B2 (ja) * 1989-09-18 1994-09-14 株式会社ミドリ十字 ヒト血清アルブミンの製造方法
ES2074490T5 (es) * 1990-03-22 2004-02-16 Biotest Pharma Gmbh Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa.
AT408191B (de) * 1991-08-19 2001-09-25 Haemosan Erzeugung Pharmazeuti Verfahren zur inaktivierung von prionen
US5486293A (en) * 1994-03-21 1996-01-23 Hemasure, Inc. Removal of small exogenous molecules from biological fluids
US5561115A (en) 1994-08-10 1996-10-01 Bayer Corporation Low temperature albumin fractionation using sodium caprylate as a partitioning agent
AUPO410696A0 (en) * 1996-12-06 1997-01-09 Csl Limited Inactivation of viruses by incubation with caprylate
AU717541B2 (en) * 1996-12-06 2000-03-30 Csl Limited Inactivation of viruses by incubation with caprylate
US5886154A (en) * 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6955917B2 (en) * 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
US20030133829A1 (en) * 2001-12-21 2003-07-17 Baxter Healthcare Corporation Process for inactivating pathogens in a biological material
CN1330370C (zh) 2002-02-28 2007-08-08 尼普洛株式会社 稳定的白蛋白制剂
US20040022792A1 (en) * 2002-06-17 2004-02-05 Ralph Klinke Method of stabilizing proteins at low pH
CA2557229C (en) 2004-02-27 2012-07-10 Octapharma Ag A method of providing a purified, virus safe antibody preparation
CN1314447C (zh) * 2004-04-12 2007-05-09 爱华生物科技(香港)有限公司 一种具有抑制蛋白酶作用的药物的制备方法
WO2005113604A2 (en) * 2004-05-14 2005-12-01 Hematech, Llc Methods for immunoglobulin purification
JP5732196B2 (ja) * 2006-11-01 2015-06-10 バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． 低ｐＨおよび二価カチオンを用いる生物高分子を単離する方法
AU2009236653B2 (en) * 2008-04-16 2014-09-25 Biogen Ma Inc. Method of isolating biomacromolecules using polyalkylene glycol and transition metals
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
DE102010054767B4 (de) 2010-12-16 2013-02-21 Previpharma Ag Verfahren zur Trennung, Aufkonzentration und/oder Reinigung von (Blut)Plasmaprotein, Viren oder Virenbestandteilen
CA2789539A1 (en) 2011-09-12 2013-03-12 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
US9347065B2 (en) 2012-03-29 2016-05-24 International Aids Vaccine Initiative Methods to improve vector expression and genetic stability
AU2013205138B2 (en) 2012-08-09 2015-06-25 Grifols, S.A. Caprylate Viral Deactivation
SG10201811186XA (en) 2013-10-18 2019-01-30 Novasep Process Purification of proteins
WO2015073633A1 (en) * 2013-11-15 2015-05-21 Genentech, Inc. Methods for viral inactivation using eco-friendly detergents
US20170044210A1 (en) 2014-04-30 2017-02-16 Novo Nordisk A/S Methods for the purification of proteins using caprylic acid
MY179524A (en) 2015-06-26 2020-11-10 Ferring Bv Methods of purification and/or viral inactivation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4440679A (en) * 1980-03-05 1984-04-03 Cutter Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4495278A (en) * 1981-04-27 1985-01-22 Baxter Travenol Laboratories, Inc. Process for making novel blood clotting enzyme compositions
JPS5874617A (ja) * 1981-10-28 1983-05-06 Green Cross Corp:The 人由来血液凝固第７因子含有水溶液の加熱処理方法
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4534972A (en) * 1983-03-29 1985-08-13 Miles Laboratories, Inc. Protein compositions substantially free from infectious agents
US4834975A (en) * 1984-05-25 1989-05-30 Genetics Corporation Human monoclonal antibodies to serotypic lipopolysaccharide determinants on gram-negative bacteria and their production
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
US4762714A (en) * 1986-04-08 1988-08-09 Miles Laboratories, Inc. Preparation of retrovirus-free immunoglobulins
FR2630115B1 (fr) * 1988-04-14 1994-10-28 Merieux Inst Procede de stabilisation des solutions d'albumine humaine et solution obtenue

Also Published As

Publication number Publication date
AU4698789A (en) 1990-06-28
EP0374625A3 (en) 1991-08-07
EP0374625B1 (en) 1992-11-19
JPH02273175A (ja) 1990-11-07
DE68903558T2 (de) 1993-04-01
JP2601551B2 (ja) 1997-04-16
CA1340211C (en) 1998-12-15
AU618157B2 (en) 1991-12-12
GR3006561T3 (https=) 1993-06-30
ATE82510T1 (de) 1992-12-15
EP0374625A2 (en) 1990-06-27
DE68903558D1 (de) 1992-12-24
US4939176A (en) 1990-07-03

Similar Documents

Publication Publication Date Title
ES2052872T3 (es) Procedimiento de inactivacion de virus.
DE3888642D1 (de) Rollflasche zur Züchtung von Zellengewebekulturen.
ATE335810T1 (de) Verfahren zur inaktivierung von lipidumhüllten viren
ATE116857T1 (de) Oligodesoxynukleotide als inhibitoren der replikation von retroviren und der expression von onkogenen.
ATE89735T1 (de) Pharmazeutische zubereitung zur behandlung von viruskrankheiten mit leber-extrakt.
ATE66140T1 (de) Salbengrundlage und salbe.
DE68917324D1 (de) Methode zur Immobilisierung von physiologisch aktiven Substanzen.
DE69631229D1 (de) Herstellung von virusinaktivierten Intravenös injektierbaren Globulin aus Immunserum
PT81372B (pt) Processo para a preparacao de glicopeptidos e de composicoes anti-bacterianas que os contem
Ansari et al. Role of glutathione in the prevention of cataractogenesis in rat lenses
AU678343B2 (en) Method and composition for determining the immunological activity of bioactive substances
ATE188124T1 (de) Transformierte zellen zur verhütung oder zur behandlung von virus-induzierten erkrankungen,besonders pathogenen retroviren
DE3767308D1 (de) Verwendung von sulfonamidderivaten zur herstellung eines antivirusmittels.
ATE41675T1 (de) Immobilisierung von katalytisch aktiven mirkoorganismen in agargelfasern.
ES2170845T3 (es) Procedimiento para la inactivacion de virus en proteinas.
ES8103161A1 (es) Metodo mejorado para la propagacion in vitro de parasitos debabesia
ES2016227A4 (es) 54- procedimiento para la elaboracion de aminoacidos l-alfa.
FI881123A0 (fi) Inaktivering av human immunodeficiency virus (hiv) medelst fenol i proteinhaltiga loesningar.
BR9307176A (pt) Métodos para identificação de um paciente contaminado com hiv para determinar a eficácia do tratamento de um paciente humano infectado com hiv e processo para identificar os indivíduos contaminados com hiv
ES2077707T3 (es) Procedimiento para la inactivacion de la actividad biologica de adn.
SE8102267L (sv) Forfarande for framstellning av ej koagulerbart blod medelst proteolytiska enzymer och proteinkoncentrat framstellt derur
Axelsson et al. A case of angioneurotic oedema with a high content of non-functioning, double peaked C1 esterase inhibitor
ATE62599T1 (de) Verwendung einer loesung von alpha-chymotrypsin.
Akanji et al. Effect of repeated administration of suramin on alkaline phosphatase activity in rat kidney.
JPS5726625A (en) Sustained release type composite material entrapping medical enzyme and its preparation

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 374625

Country of ref document: ES